Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boehringer Ingelheim granted priority review for atrial fibrillation drug

Boehringer Ingelheim granted priority review for atrial fibrillation drug

2nd September 2010

Boehringer Ingelheim has been granted priority review status by a key healthcare regulator for dabigatran etexilate, its innovative new treatment for atrial fibrillation sufferers.

The US Food and Drug Administration (FDA) has given the designation for the novel oral direct thrombin inhibitor, which is intended to help prevent strokes, based on positive data from the recent RE-LY clinical trial.

This decision recognises the fact that dabigatran etexilate represents a significant advance in an area where no comparably adequate therapy exists.

Registration submissions for the drug are also ongoing in Europe, Japan and other territories, with Boehringer Ingelheim expecting the first approval of the treatment to be issued later this year or in early 2011.

Professor Klaus Dugi, corporate senior vice-president for medicine at Boehringer Ingelheim, said: "The decision by the US FDA to grant a priority designation review is an important step in making dabigatran etexilate available for patients with atrial fibrillation to prevent them from strokes."

This comes in the same month that the company, which was founded in 1885, marks its 125th anniversary.ADNFCR-8000103-ID-800048792-ADNFCR

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.